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through F-actin remodelingHeike Naumann 1, Thomas Rathjen 2, Matthew N. Poy 2, Francesca M. Spagnoli 1,3,*ABSTRACT
Objective: Actin cytoskeleton remodeling is necessary for glucose-stimulated insulin secretion in pancreatic b-cells. A mechanistic under-
standing of actin dynamics in the islet is paramount to a better comprehension of b-cell dysfunction in diabetes. Here, we investigate the Rho
GTPase regulator Stard13 and its role in F-actin cytoskeleton organization and islet function in adult mice.
Methods: We used Lifeact-EGFP transgenic animals to visualize actin cytoskeleton organization and dynamics in vivo in the mouse islets.
Furthermore, we applied this model to study actin cytoskeleton and insulin secretion in mutant mice deleted for Stard13 selectively in pancreatic
cells. We isolated transgenic islets for 3D-imaging and perifusion studies to measure insulin secretion dynamics. In parallel, we performed
histological and morphometric analyses of the pancreas and used in vivo approaches to study glucose metabolism in the mouse.
Results: In this study, we provide the first genetic evidence that Stard13 regulates insulin secretion in response to glucose. Postnatally, Stard13
expression became restricted to the mouse pancreatic islets. We showed that Stard13 deletion results in a marked increase in actin poly-
merization in islet cells, which is accompanied by severe reduction of insulin secretion in perifusion experiments. Consistently, Stard13-deleted
mice displayed impaired glucose tolerance and reduced glucose-stimulated insulin secretion.
Conclusions: Taken together, our results suggest a previously unappreciated role for the RhoGAP protein Stard13 in the interplay between actin
cytoskeletal remodeling and insulin secretion.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Pancreatic b-cells play a fundamental role in maintaining blood
glucose homeostasis. Not only do they produce insulin but also they
secrete the hormone in response to increases in blood glucose con-
centration [1,2]. Glucose-stimulated insulin secretion (GSIS) is the
principal mechanism of insulin release by the b-cell [3e5]. This
process coincides with actin cytoskeleton remodeling, during which
glucose metabolites induce localized depolymerization of filamentous
actin (F-actin) [3,6].
The actin cytoskeleton plays a complex role in regulating insulin
release: it acts as a physical barrier, impeding the access of insulin
granules to the cell periphery, but it also actively participates in it by
providing a cytoskeletal track for insulin granule transport [4,6e10].
Yet, the molecular mechanisms responsible for F-actin remodeling in
b-cells and their impact on insulin release are not clearly understood.
Importantly, alterations in insulin secretion lead to type 2 diabetes
[4,11]. Therefore, improving our understanding of how the cytoskel-
eton controls insulin secretion might shed new light on the patho-
physiology of the disease as well as help to identify novel therapeutic
strategies.
Actin cytoskeleton remodeling is regulated by the Rho-family of small
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twenty members; Cdc42, Rac, and Rho are the best characterized
members and most studied as regulators of actin assembly, each
controlling the formation of filopodia, lamellipodia, and stress fibers,
respectively [12,14]. Small GTPases cycle between a GTP-bound
(active) and GDP-bound (inactive) conformation. This process is
tightly regulated by distinct classes of proteins, including the guanine
nucleotide exchange factors (GEFs), which mediate activation, the Rho
GTPases-activating proteins (GAP), which lead to inactivation, and the
guanine nucleotide dissociation inhibitors (GDI) [14,15]. Several
studies have indicated Cdc42 and Rac1 GTPases as well as their
effector protein PAK1, the GEF protein Tiam1, and RhoGDI as partic-
ularly important for glucose-stimulated insulin secretion in vivo and
in vitro in mouse b-cells [6,13,16e19]. The Rho-ROCK pathway has
also been implicated in b-cell function and insulin secretion
[17,20,21]. For instance, pharmacological inhibition of Rho and ROCK
leads to a significant increase in actin depolymerization and GSIS in rat
primary b-cells and mouse insulinoma 6 (MIN6) cells [20,21]. How-
ever, the in vivo roles of Rho and Rho-dependent actin remodeling in
insulin secretion remain to be assessed. To date, these investigations
have been mostly hampered by the lack of suitable genetic models for
studying actin remodeling and Rho signaling in vivo in b-cells. In
particular, the reliable visualization of F-actin structures with sufficientk Center for Molecular Medicine, Robert-Roessle Strasse 10, Berlin 13125,
Berlin 13125, Germany 3Berlin Institute of Health (BIH), Berlin, Germany
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resolution and without interfering with cytoskeleton dynamics have
represented a critical limitation to overcome.
To fill these gaps and gain insight into how actin cytoskeleton regulates
insulin secretion, we used the Lifeact-EGFP transgenic mice to visu-
alize F-actin in b-cells [22]. Further, we applied this model to study
in vivo actin cytoskeleton and insulin secretion in mice deficient for the
Rho GTPase regulator RhoGAP Stard13 that we previously identified in
embryonic pancreas [23]. Postnatally, Stard13 expression became
restricted to the pancreatic islets. Here, we showed that Stard13
deletion results in a marked increase in actin polymerization in islet
cells, which is accompanied by severe reduction in insulin secretion in
perifusion experiments. Consistently, animals displayed impaired
glucose tolerance and reduced GSIS. Taken together, our results
suggest a previously unappreciated role of the RhoGAP protein Stard13
as a key component of the insulin secretion machinery through actin
cytoskeletal remodeling.
2. MATERIALS AND METHODS
2.1. Mouse strains, phenotypic characterization, and tissue
preparation
The following mouse strains were used: Stard13floxtm1.1FMS mice [23],
B6.FVB-Tg(Ipf1-cre)1Tuv/Nci [24], Tg(Ins2-cre)23Herr [25], Tg(CAG-EGFP)
#Rows [22]. All animal experiments were performed in accordance with
the rules and regulations of the LaGeso local authority. Efficiency of
recombination in the Pdx1-Cre line was previously assessed in [23].
For the glucose tolerance test (GTT), mice were fastened overnight and
blood was collected before and after intraperitoneal injection of
glucose (2 g/kg body weight) at 15, 30, 60, and 120 min. Blood
glucose levels were determined using a glucometer (Contour, Bayer).
For glucose-stimulated insulin secretion (GSIS), fasted animals were
injected intraperitoneally with glucose (2 g/kg body weight). Plasma
insulin concentration was measured by an ultra-sensitive mouse in-
sulin ELISA kit (Crystal Chem. Inc., Downers Grove, USA) at 0, 2, 5,
15 min time points after glucose injection. Plasma insulin concentra-
tion from random fed mice was determined by radioimmunoassay kit
(Rat Insulin RIA #RI-13K, Merck-Millipore). For the measurement of
insulin content, the pancreata were excised and weighted, and insulin
was extracted by homogenization using a glass-Teflon homogenizer in
acidic ethanol (2% concentrated HCl in 100% ethanol). After centri-
fugation, supernatants were collected, and the immunoreactive insulin
in the supernatant was measured by radioimmunoassay kit (Rat Insulin
RIA #RI-13K, Merck-Millipore).
2.2. Imaging analysis on isolated islets
For imaging analysis, islets were isolated from transgenic and non-
transgenic control mice by collagenase digestion (640 U) at 37 C
for 15 min with mild shaking, as described previously [26]. Islets were
picked by hand selection under a dissecting microscope, plated into
channel slides (m-slide VI 0.4, Ibidi, #80,606) and cultured overnight in
RPMI 1640 medium supplemented with 10% FCS unless differently
stated. Islets were stimulated afterwards with 8 or 16 mM glucose,
where indicated. The next day, Z-stack acquisition of Lifeact-EGFP
fluorescence was performed on a Zeiss LSM 700 confocal micro-
scope. Subsequently, the islets were fixed for 30 min in 4% para-
formaldehyde at RT and subjected to immunostaining analyses. Briefly,
islets were permeabilized with 1% Triton X-100 in PBS for 20 min,
blocked for 30 min in 10% donkey serum blocking solution and,
subsequently, incubated with the indicated primary and secondary
antibodies diluted in 1.5% donkey serum overnight at 4 C. For
latrunculin B treatment, islets were pre-incubated in the presence ofMOLECULAR METABOLISM 8 (2018) 96e105  2018 The Authors. Published by Elsevier GmbH. This is an ope
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Images and time-lapse movies (45 s interval using a 63 oil objective)
were acquired on a Zeiss LSM 700; 3D projections and rendering were
created using Zen 2010, Imaris 7.6.5 and ImageJ software.
2.3. Perifusion assays in isolated islets
Pancreatic islets were isolated from transgenic and non-transgenic
control animals, as described above, and cultured overnight in RPMI
1640 medium supplemented with 10% FCS. We performed islet
perifusion assays as previously described [27]. Briefly, 50 islets per
condition were placed on a nylon filter in a plastic perifusion chamber
and perifused with a modified KRBH buffer (137 mM NaCl, 2.7 mM KCl,
0.9 mM CaCl2, 0.5 mM MgCl2, 1.5 mM KH2PO4, 8.1 mM NaH2PO4,
20 mM Hepes pH 7.4, 0.2% BSA) containing various concentrations of
glucose at a constant flow rate of 0.1 ml/min using the BioRep Peri-
fusion System (Model No. PERI-4.2) maintained at 37 C. Prior to
fraction collection, the islets were primed for 30 min in a buffer
containing 5.5 mM glucose and, subsequently, perifused with low-
glucose (3.3 mM) for 8 min, followed by 15 min high-glucose
(16.7 mM), 15 min low-glucose (3.3 mM) and a final step with
30 mM KCl þ 3.3 mM glucose for 8 min.
Where indicated, islets were primed in the presence of 10 mM
latrunculin B (Calbiochem #4,28,020) for 30 min and subsequently
perifused with latrunculin B under low and high glucose stimulatory
conditions as above. The fractions were collected every 1 min and
insulin measured by radioimmunoassay (Rat Insulin RIA #RI-13K,
Merck-Millipore).
2.4. Immunofluorescence and morphometric analyses
Mouse pancreata were fixed in 4% paraformaldehyde at 4 C over-
night. Subsequently, samples were equilibrated in 20% sucrose so-
lution, embedded in Tissue-Tek OCT compound (Sakura, #4583) and
cryosectioned at 10 mm-thickness. Immunofluorescence staining on
cryosections was performed as previously reported [23]. Primary an-
tibodies are listed in Supplementary Table 1. Image acquisition was
done with a Zeiss LSM 700 confocal microscope. Briefly, for the
morphometric analysis of the islets, the entire pancreas of 3 controls
and 3 mutants per time-point was sectioned. Sections were stained for
Insulin, Glucagon and Hoechst, imaged by tile-scan acquisition and
evaluated at 100e300 mm interval for 6 M pancreata. Islet areas were
measured using the AxioVision software (Zeiss). For the analysis of
islet cellular composition, the insulin- and glucagon-specific areas
were measured on confocal lsm files using the ROI tool in ImageJ.
Fluorescence intensity was quantified in ImageJ software on split
channels using the integrated density and corrected total cell fluo-
rescence (CTCF) tools in individual cells or islets.
For z-stack analysis, individual islets in individual z-planes were
defined as ROI, the fluorescence intensity within the ROIs was
measured and the sum intensity values of multiple z-planes calculated.
All results are expressed as mean  s.e.m., and significance of dif-
ferences between groups was evaluated with Student’s t-test.
2.5. TEM
Pancreata from adult mice were fixed in phosphate-buffered 4%
formaldehyde and post-fixed in 2% formaldehyde and 1% glutaral-
dehyde. After treatment with 1% OsO4, the samples were dehydrated
and embedded in Poly/Bed 812 (Polysciences, Inc., Eppelheim, Ger-
many). Ultrathin sections were stained with uranyl acetate and lead
citrate and examined using a FEI Morgagni electron microscope. Digital
images were taken with a Morada CCD camera and the iTEM software
(Olympus Soft Imaging Solutions GmbH, Münster, Germany).n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 97
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All results are expressed as mean  standard deviation (s.d.) or
standard error (s.e.m.), as indicated. Each experiment was repeated
multiple times independently (at least  3). The significance of dif-
ferences between groups was evaluated with Student’s t-test or two-
way ANOVA test, as appropriate. p < 0.05 was considered statistically
significant.
3. RESULTS
3.1. Lifeact-EGFP labels F-actin in mouse pancreatic islets in vivo
Visualization of F-actin in living cells is critical for the study of cyto-
skeleton dynamics and actin-dependent cellular processes, such as
cell migration, polarization, and regulated exocytosis [28]. Lifeact is a
17-amino-acid-long actin-binding peptide derived from yeast that
specifically labels F-actin without affecting actin organization and
dynamics [22]. The Lifeact-EGFP probe has been used previously to
label individual cells in isolated mouse islets by adenoviral over-
expression [29]. Here, to visualize the in vivo organization of actin
cytoskeleton and F-actin dynamics in pancreatic islets, we used
transgenic mice ubiquitously expressing the Lifeact peptide fused to
EGFP, known as Lifeact-EGFP mice [22] (Figure 1). We isolated islets
from adult pancreas of transgenic Lifeact-EGFP mice and character-
ized them by three-dimensional (3D) culturing and imaging (Figure 1).Figure 1: Characterization of the Lifeact-EGFP transgenic mouse islets. A) Schema
peptide fused to EGFP is driven by CAG promoter [22]. Islets were isolated from Lifeact-E
native Lifeact-EGFP (green) in live pancreatic islets. On the left, representative maximum
cultured for 12 h in the presence of glucose (16 mM); on the right, a single optical se
pronounced at the cellular edges (arrows) than along the cell faces (arrowheads). This is c
adenoviral infection of isolated mouse islets [29]. C) Representative single plane confocal
islets for Phalloidin in red and Lifeact-EGFP in green. Insets show split channels (green and
confocal image of whole-mount immunofluorescence of Lifeact-EGFP transgenic mouse
33342 was used as nuclear counterstain. Insets show split channels of boxed area at highe
10 um.
98 MOLECULAR METABOLISM 8 (2018) 96e105  2018 The Authors. Published by Elsevier GmbH. ThNative Lifeact-EGFP was directly acquired in living cells of islets
cultured for 12 h in the presence of glucose (16 mM) (Figure 1B) as
well as after fixation and whole-mount immunostaining (Figure 1C,D).
In both conditions, we found that the actin cytoskeleton is labeled in all
cells of the Lifeact-EGFP transgenic islets (Figure 1). Importantly,
Lifeact-EGFP overlapped with Alexa Fluor 555-conjugated phalloidin
staining, though the Lifeact-EGFP signal was brighter enabling visu-
alization of F-actin in all types of specialized structures with a better
signal-to-noise ratio compared to phalloidin (Figure 1C). To further
characterize Lifeact-EGFP transgenic islets, we performed whole-
mount immunostaining with antibodies against endocrine cell-
specific markers, such as glucagon and insulin (Figure 1D). Lifeact-
EGFP transgenic mouse islets displayed typical cellular composition
and architecture, with glucagon cells at the periphery of the islet,
forming a mantle-like structure, and insulin-positive cells in the core
and representing the majority of the cells. In summary, islets isolated
from Lifeact-EGFP mice are ideally suited for visualizing the actin
cytoskeleton in islets and individual b-cells in situ.
3.2. Stard13 deficiency perturbs F-actin cytoskeleton organization
in adult islets
Actin cytoskeleton dynamics is regulated by small GTPases of the Rho
family [14,28], but how Rho signaling is locally controlled in pancreatic
islets remains to be fully elucidated. Proteins of the RhoGAP family aretic representation of the Lifeact-EGFP transgenic construct. Expression of the Lifeact
GFP adult mice and cultured either for 3D imaging or perifusion assays. B) Imaging of
intensity projection (MIP) of consecutive optical sections of a pancreatic mouse islet
ction (Single plane). Lifeact-EGFP signal labels all islet cells with a distribution more
onsistent with the labeling distribution observed in individual b-cells upon Lifeact-EGFP
image of whole-mount immunofluorescence staining of Lifeact-EGFP transgenic mouse
red) of boxed area; arrows indicate overlapping stainings. D) Representative single plane
islets for glucagon (Gluca, red) and insulin (Ins, blue), in green Lifeact-EGFP. Hoechst
r magnification; stars indicate glucagon-positive cells which are negative for insulin. Bar,
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Disorganization of F-actin cytoskeleton in the absence of Stard13 in pancreatic islets. A) Imaging of native Lifeact-EGFP (green) in Lifeact control and Life-
act;Stard13DPA pancreatic islets. Representative MIPs and single optical sections of islets cultured for 12 h in the presence of low (2 mM) and high glucose (16 mM). Arrowheads
indicate staining along the cell membranes; arrows indicate cellular edges. Bar, 20 um. B) Dot plot quantification of Lifeact fluorescence intensity in control and Stard13DPA islets.
(n ¼ 10 islets from three independent pancreatic samples per genotype) *p < 0.05. C) Ratio of G-actin and F-actin fluorescence intensity in control and Stard13DPA islets. Adult
pancreatic tissue sections were stained with Phalloidin-Alexa Fluor 555 and Deoxyribonuclease I-Alexa Fluor 488 for the simultaneous detection of filamentous actin (F-actin)
and unpolymerized actin (G-actin), respectively (Supplementary Fig. 2). Quantification was performed on at least 12 islets, 5 cells per islet, from three independent pancreatic
samples per genotype. *p < 0.05 D) Immunofluorescence analysis on cryosections of adult pancreatic tissues from Lifeact control and Lifeact;Stard13DPA transgenic animals.
Glucagon (Gluca, red), insulin (Ins, blue), in green Lifeact-EGFP and Hoechst 33342 was used as nuclear counterstain. Insets show EGFP and Hoechst channels of boxed area at
higher magnification. Bar, 50 um.prime candidates for such activity [14,15]. We previously identified a
Rho-GTPase regulator, the RhoGAP Stard13, for being expressed in the
pancreas throughout embryonic development and required for F-actin
cytoskeleton remodeling in pancreatic progenitors [23]. Interestingly,
shortly before birth Stard13 expression became restricted to the
endocrine islets (Supplementary Fig. 1). To investigate whether
Stard13 plays a role in the organization of the actin cytoskeleton in
adult islets, we generated a pancreas-specific deletion of Stard13
using Pdx1-Cre (Stard13flox/flox;Pdx1-Cre; hereafter referred to as
Stard13DPA), as previously reported [23]. Next, to visualize F-actin
organization, we intercrossed the Stard13DPA and Lifeact-EGFP
transgenic mice (hereafter referred to as Lifeact;Stard13DPA). Pdx1-
Cre negative littermates served as negative controls. To perform 3D
imaging of intact islets, we isolated pancreatic islets from Life-
act;Stard13DPA and control animals and examined native Lifeact-EGFP
in living cells (Figure 2A). Importantly, we found marked differences in
F-actin cytoskeleton organization between control and Stard13DPA islet
cells: control cells displayed a thin cortical actin network and fine-MOLECULAR METABOLISM 8 (2018) 96e105  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.commesh structures, while in mutant cells the meshwork’s density was
increased and bundles of actin fibers were visible beneath the cell
membrane (Figure 2A). The increase in F-actin density was also re-
flected in the higher levels of Lifeact-EGFP fluorescence intensity in
mutant islets compared to controls; by contrast, no differences were
measured in insulin staining and distribution of membrane markers,
including E-cadherin and GLUT2, which displayed a normal edge and
vertex organization [29,30] (Figure 2B, Supplementary Figs. 2AeC). A
similar abnormal cytoskeleton arrangement was also detectable on
fixed adult pancreatic tissues of Stard13DPA animals, which displayed
an accumulation of F-actin in islets embedded in their native envi-
ronment (Figure 2D). To further characterize the cytoskeleton changes
observed in the absence of Stard13, we used fluorescent probes for
simultaneous detection of monomeric globular actin (G-actin) and
filamentous actin (F-actin) in pancreatic islets [12,14] (Supplementary
Fig. 2D). In line with F-actin accumulation, we found that the ratio
between G-actin and F-actin is decreased in mutant islets as
compared to controls (Figure 2C).n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 99
Figure 3: Stard13 is required for F-actin cytoskeleton remodeling in islets upon glucose stimulation. A) Representative still image frames from time-lapse experiments of
Lifeact control and Lifeact;Stard13DPA living pancreatic islets cultured in the presence of low glucose (2 mM) and then stimulated with high glucose (16 mM). Arrowheads indicate
native Lifeact-EGFP (green) along the cell membranes. Actin remodeling upon addition of glucose is visible in control islets but not in the mutants. Bar, 20 um. B) Quantification of
Lifeact fluorescence intensity in control and Lifeact;Stard13DPA islets cultured with low (2 mM) and high glucose (16 mM). (n ¼ 10 islets). *p < 0.05. C) Immunofluorescence
analysis of insulin (green) and glucagon (red) on control and Stard13DPA adult pancreatic tissues. Hoechst (blue) was used as nuclear counterstain. Bar, 50 um. D) Morphometric
analysis of islet surface area in control and Stard13DPA pancreata at 6 months. Islet sectional area was normalized versus the total pancreas area. (n ¼ 5). E) Portion of insulin and
glucagon area versus total area in adult control and Stard13DPA mouse islets. (n ¼ 10 mice). p < 0.001.
Original Article3.3. Stard13 is required for actin remodeling in b-cells during GSIS
Glucose stimulation rapidly promotes F-actin remodeling to mobilize
insulin granules to the cell periphery, which is a requisite for proper GSIS
from the b-cells [6]. Notably, time-lapse imaging of whole islets showed
that the F-actin network remained intact in Lifeact;Stard13DPA islets and
its abnormal distribution did not change in response to increasing
concentration of glucose, which instead occurred in control islets100 MOLECULAR METABOLISM 8 (2018) 96e105  2018 The Authors. Published by Elsevier GmbH. Th(Figure 3A,B). These results suggest that Stard13 activity is required for
actin remodeling in b-cells in response to glucose stimulation.
Next, we asked whether the F-actin accumulation and disorganization
observed in Stard13DPA islets affect insulin secretion dynamics. To this
aim, we performed islet perifusion studies (Figure 4A). Islets were
isolated from control and Stard13DPA adult mouse pancreas and
challenged with increasing concentration of glucose. At low levels ofis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
glucose (3.3 mM), insulin secretion did not measurably differ between
mutant and control islets. By contrast, in high glucose conditions
(16.7 mM), islets from Stard13DPA mice exhibited a significant
reduction in insulin release compared to control islets during both first
and second-phase secretion (Figure 4A). Islets from Stard13DPA mice
had blunted insulin secretion in response to KCl-stimulation too, which
is compatible with a disrupted F-actin network [10,31] (Figure 4A).
Accordingly, we previously reported that Stard13DPA mice displayed
impaired glucose tolerance at three months after birth when compared
to control animals of the same age [23]; this defect became more
pronounced with aging (Supplementary Fig. 3). The basal plasma in-
sulin levels did not differ between mutant and control animals
(Figure 4C), while the increase in plasma insulin in response to glucose
injection was blunted in Stard13DPA mice when compared to controls
(Figure 4D). Together, the in vivo GSIS and the reduced ability of
Stard13DPA mice to clear blood glucose in the GTT experiment are
consistent with the islet perifusion results, suggesting a function ofFigure 4: Insulin secretion is reduced in Stard13-deficient mouse models. A) Dyna
incubated in KRBH buffer containing 3.3 mM glucose (low) were stimulated with 16.7 mM
indicated. Insulin release kinetics showed biphasic responsiveness from islets isolated from
fractions are presented as secreted insulin normalized to islet insulin content (n ¼ 3 anim
insulin in the random-fed condition is similar between control and Stard13DPA mice (n ¼ 6).
in Stard13DPA mice compared to control animals. (n ¼ 7) *p < 0.05.
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Decreased insulin secretion could also reflect changes in b-cell mass,
differentiation state, and/or defects in insulin production or granule
biogenesis [32e34]. To distinguish among these possibilities, we first
examined the endocrine islet area and pancreatic insulin content,
which were both comparable between age-matched control and
Stard13DPA mice (Figures 3C,D, 4B). The architecture of Stard13DPA
islets overall resembled that of control islets, displaying the typical
presence of b-cells within the islet core and a-cells at the periphery
(Figure 3C). Quantification of cellular composition revealed a slight but
significant increase (w6%) in a-cells versus b-cell area in Stard13-
deficient mice compared with controls (Figure 3E). Nevertheless, this is
unlikely to account for the reduced insulin secretion seen in the per-
ifusion experiment.
To determine whether insulin secretory vesicle formation was impaired
in the absence of Stard13, we employed transmitted electronmics of GSIS by islet perifusion from control and Stard13DPA mouse pancreas. Islets
glucose (high), returned to low conditions, and finally, perifused with 30 mM KCl, as
control mice that mimicked those previously reported [39]. Insulin values in collected
als per genotype). ANOVA test, p < 0.001. B) Pancreas insulin content and C) plasma
D) Plasma insulin after intraperitoneal injection of glucose (2 g/kg body weight) is lower
n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 101
Figure 5: Insulin secretion is restored in Stard13-deficient islets upon treatment with latrunculin. A) Representative single plane confocal images of Lifeact control and
Lifeact;Stard13DPA pancreatic islets cultured for 30 min in KRBH buffer (supplemented with 5.5 mM Glucose) in the presence of DMSO or 10 mM Latrunculin B (Lat). Bar, 20 mm. B)
Representative islet perifusion assay from control and Stard13DPA mouse pancreas either left untreated or treated with 10 mM Latrunculin B during the entire duration of the
perifusion assay. Isolated islets were first incubated in KRBH buffer containing 5.5 mM glucose (priming) for 30 min; next, the islets were first exposed to 3.3 mM glucose (low),
stimulated with 16.7 mM glucose (high), returned to low conditions, and, finally, perifused with 30 mM KCl, as indicated. Insulin values in collected fractions are presented as
secreted insulin normalized to islet insulin content. (n ¼ 3). C) GSIS assay by islet perifusion from control and Stard13DBeta mice. Insulin content in collected fractions is presented
as secreted insulin normalized to islet insulin content percentage of insulin secreted (n ¼ 3). ANOVA test, p < 0.001.
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microscopy (TEM). Ultrastructural examination of b-cells from control
and Stard13DPA islets revealed the presence of mature and immature
insulin granules in a similar proportion (Supplementary Figs. 3E,F),
ruling out impaired insulin granule biogenesis. Taken together, these
findings suggest that insulin production and storage are not signifi-
cantly affected in the mutant pancreas, but the observed defects in
insulin secretion arise from impaired F-actin remodeling.
To directly address whether actin organization is responsible for the
insulin secretion defects, we treated the Stard13DPA islets with the actin
depolymerization agent latrunculin B and, subsequently, performed islet
perifusion studies (Figure 5). As expected, latrunculin B treatment
rapidly abolished cortical actin staining in islets, consistent with pre-
vious reports [10,20,36]. Specifically, we found that cortical F-actin
becomes fragmented into small clusters scattered throughout the cells
of both control and Lifeact;Stard13DPA islets (Figure 5A). Moreover,
exposure to latrunculin B markedly potentiated GSIS when compared
with untreated islets from both control and mutant Stard13DPA mice
(Figure 5B). These results indicate that insulin secretion is rescued
when actin is depolymerized in mutant islets, further supporting a role
for Stard13 in F-actin cytoskeleton remodeling in the b-cell.
3.4. Stard13 is required for insulin secretion in b-cells
Finally, to determine the function of Stard13 specifically in b-cells, we
generated Stard13flox/flox;RIP-Cre [25] (hereafter referred to as
Stard13DBeta) mice. Deletion of Stard13 in differentiating b-cells did
not affect pancreas formation and organ weight (Supplementary
Fig. 3), which is different from the early phenotype associated with
the Stard13DPA pancreata [23]. Nevertheless, Stard13 deficiency in b-
cells had a direct impact on insulin release from isolated perifused
mouse islets (Figure 5C). Specifically, we found a reduction of insulin
secretion in response to glucose in Stard13DBeta perifused islets as
compared to control adult islets, whereas total insulin content in the
isolated islets and insulin plasma levels in fed state were unchanged
(Supplementary Fig. S3 and data not shown). Note that differences in
the insulin secretion response of control islets were visible during the
perifusion experiments (Figures 4A, 5B,C) To avoid these variations,
that are possibly due to islet preparation, we always isolated and
simultaneously tested both control and mutant islets for each peri-
fusion assay shown in this study.
Together, these results revealed that GSIS is impaired when Stard13 is
deficient in b-cells and are consistent with the impaired glucose-
responsive insulin secretion observed in Stard13DPA islets.
4. DISCUSSION
In this study, we have uncovered the essential role of the RhoGAP
Stard13 in ensuring insulin secretion in response to glucose. Inter-
estingly, Stard13 played a prominent role in both acute and secondary
phases of GSIS, with no effect on insulin granule biogenesis, insulin
content and b-cell morphology. Deletion of Stard13 destabilized the b-
cell cytoskeleton, leading to a thicker and disorganized F-actin
network, and hampered its remodeling in response to glucose.
Importantly, latrunculin B-dependent depolymerization of F-actin re-
stores insulin secretion in islets from Stard13-deficient pancreas.
Taken together, these results suggest that F-actin cytoskeleton
remodeling is under the local control of the RhoGAP Stard13 in the b-
cell.
The continuous turnover of cortical actin filaments enables animal cells
to quickly respond to external stimuli and readily adapt to mechanical
cues or biochemical signaling [28]. A prime example of this is repre-MOLECULAR METABOLISM 8 (2018) 96e105  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comsented by the GSIS in pancreatic b-cells, wherein glucose stimulation
rapidly promotes F-actin remodeling to mobilize insulin granules to the
cell periphery [6]. Consistently, treatment with the actin depolyme-
rizing agent latrunculin B has been demonstrated to potentiate GSIS
[10]. Additionally, F-actin-associated proteins, such as MLCK, myosin
IIA, and FAK, have been implicated in insulin release [6,8,35e37]. Our
study indicates Stard13 as a novel regulator of actin organization and
function in b-cells that may occur through both direct and indirect
mechanisms. We previously reported that Stard13 regulates Rho
signaling during pancreas development [23]. In the absence of
Stard13, uninhibited Rho activity hampered actin cytoskeleton
remodeling, leading to F-actin fibers accumulation in mouse pancre-
atic progenitor cells [23]. Here, our results suggest a functionally
conserved role for this RhoGAP protein in adult islets, underlying
cortical F-actin depolymerization during insulin secretion from b-cells.
The impact of Stard13 deficiency is indeed measurable only upon
glucose challenge, but not in low-glucose conditions. This is also
supported by the glucose intolerance phenotype observed in
Stard13DPA mice and it can explain the absence of an overt diabetic
phenotype in these mutant animals.
Focal adhesion actin-remodeling events also contribute to insulin
secretion [6,36]. Both genetic inactivation and pharmacological inhi-
bition of FAK have suggested its indirect regulation of F-actin
remodeling and insulin secretion [35,36]. Importantly, Stard13 has
been shown to localize to focal adhesions and, in certain contexts, to
spatially regulate RhoA activation at these specialized structures [38].
It is therefore possible that Stard13 might regulate GSIS through focal
adhesion actin-remodeling events and not only through cortical actin
remodeling. Finally, crosstalk between different Rho GTPases family
members is known to regulate various cellular processes and might be
at play in insulin secretion too [14]. Further investigation is required to
address whether in the absence of Stard13 the uninhibited Rho activity
might indirectly affect Cdc42 or Rac1, which are well-recognized
regulators of the second-phase insulin secretion [6,13,39].
The mechanisms that regulate actin cytoskeleton dynamics (e.g. as-
sembly and disassembly) in vivo are poorly understood, largely
because of the difficulty to visualize filamentous F-actin structures.
Lifeact is widely used for F-actin visualization in cells and tissues
without significantly interfering with actin dynamics in vitro or in vivo
[22,40]. Here, we found a strong expression of the Lifeact-EGFP
transgene in vivo in b-cells and a clear labeling of the actin cyto-
skeleton. Thus, Lifeact-EGFP transgenic animals are likely to be a
useful tool for further elucidating the role of actin in trafficking and
exocytosis of insulin secretory granules as well as the mechanisms
underlying actin regulation in the b-cells. For instance, such in vivo
model will enable to address in details the mechanisms underlying
Stard13-mediated insulin secretion function by characterizing the actin
microtubule-mediated transport of the granules over time as well as
their relationship with focal adhesions [9,35,36,41].
Alterations in insulin secretion are among the causes of diabetes [11].
Our data support a specific role of Stard13-mediated actin remodeling
in the regulation of GSIS in b-cells and highlight its potential relevance
to the pathogenesis of type 2 diabetes. In line with this, the Rho-ROCK
pathway has been previously implicated in diabetes [8,20,42]. For
example, the expression of RhoA has been reported to be increased in
pancreatic islets of diabetic mouse models [20,21]. Furthermore,
human islets of patients with type 2 diabetes exhibit a strong decrease
in PAK1, a downstream effector of Cdc42 and Rac1 signaling [16].
Collectively, these findings highlight the importance of the Rho-actin
cytoskeleton in b-cell function and might have importantn access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 103
Original Articleimplications for the understanding of b-cell dysfunction in type 2
diabetes and the development of possible therapeutic targets for the
disease.
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